Navigation Links
New HAE Drug Candidate from Dyax Produced by Laureate Biopharma
Date:8/26/2013

PRINCETON, N.J., Aug. 26, 2013 /PRNewswire/ -- Laureate Biopharma is pleased to announce its successful collaboration with Dyax Corp. for process development and cGMP production of a new treatment candidate for hereditary angioedema (HAE).  The drug candidate, known as DX-2930, is a fully human IgG antibody designed to prevent HAE attacks by inhibition of plasma kallikrein. Dyax, a biopharmaceutical company focused on HAE and other plasma kallikrein disorders, recently announced the start of a Phase 1 clinical trial evaluating the safety and tolerability of DX-2930.

In working with the cell line producing DX-2930, Laureate's scientists were able to successfully scale-up and manufacture a high-titer antibody process. This process was amendable to cGMP production in both stainless-steel and single-use bioreactors. Application of Laureate's platform downstream process for IgG antibodies led to high protein recovery and purity. Aseptic filling, a routine operation at Laureate, produced the clinical drug product in 98% yield. Finally, careful project management of the program by both companies resulted in the successful release of bulk drug substance.

"Entry into human subjects is an important milestone for the DX-2930 development program," said Gustav Christensen, President and CEO of Dyax.  "It was a pleasure to work with Laureate's scientific and program management team.  This valuable partnership has enabled us to advance this fully human monoclonal antibody into the clinic and closer toward our goal of a new therapeutic for the prevention of HAE attacks."

"This project showcased Laureate's scientific expertise in rapid development of efficient, high-yielding processes for clinical production of therapeutic antibodies," noted Michiel E. Ultee, Ph.D., Laureate's Chief Scientific Officer. "Our scientists have produced a wide variety of antibodies f
'/>"/>

SOURCE Laureate Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Xiangxue Pharmaceuticals to Acquire Rights for a Promising Drug Candidate from Kinex Pharmaceuticals for the Greater China Territory
4. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
5. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
6. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
7. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
8. New Candidate Drug Stops Cancer Cells, Regenerates Nerve Cells
9. Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
10. Test Results Show Unprecedented Achievement for Marburg Drug Candidate
11. As Tuberculosis Grows More Difficult to Control, Vaccine Candidate to Prevent Disease Enters Clinical Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
(Date:1/22/2015)...  BiOptix is pleased to announce the appointment of Dr. ... and Biochemistry. Scott joins the company after previous scientific leadership ... the course of his nearly 20 year career in ... nationally recognized thought leader in the biosensor field and ...
(Date:1/22/2015)... 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... therapies for cardiovascular disease and overall health is pleased to ... 2014 and its outlook for 2015 from the CEO, Mr. ... We would like to take this opportunity to share ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
...  BSI,s Healthcare Solutions Group is hosting a free webinar on ... is scheduled for January 26 and is intended to address ... how to be prepared. (Logo: http://photos.prnewswire.com/prnh/20110405/NE77664LOGO ... to help the audience understand the current status and upcoming ...
... (Nasdaq: CDXS ) today announced that the Company,s ... his decision to resign as Chief Financial Officer in order ... Board of Directors will conduct an immediate search for a ... contributions to Codexis," said Alan Shaw, Ph. D, President and ...
Cached Medicine Technology:FREE Webinar: Revision of the In Vitro Diagnostic Directive 2
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... State Forestry Institute of Mecklenburg-Vorpommern in ... support from GEOSYSTEMS, a dedicated Hexagon Geospatial and Intergraph ... Hexagon Geospatial’s ERDAS APOLLO for cataloging, managing, ... point clouds and documents. This effort will enable the ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... which are a risk factor for diabetes and heart disease ... research from Wake Forest University Baptist Medical Center. Early results ... to the equation. ,“The message is very clear,” said ... Baptist and lead author. “Exercise is important to reducing the ...
... Minister V.S. Achuthanandan to immediately ban the sale of Coke ... may finally get its due. ,Despite the healthy, nourishing ... have been low. Now, with the controversy over the pesticide ... a furore again, the government is going to redouble efforts ...
... the presence of drugs and not the intoxication or damage caused ... will affect their performance? // Probably not," says Paul Dillon of ... for instance, detection could mean the impairment is from quite a ... month) and really has no effect on them at the time." ...
... tend to nap after a heavy lunch. When people are ... in the brain send signals that keep a person alert. ... prevents the nerve cells from sending alert signals and hence ... that when the body needs fuel in form of glucose, ...
... looks awful. Worse, it's a real possibility for men who smoke.// ... the papilla on the tongue, normally only one mm in length, ... brown, says Joachim Dissemond of the University of Essen. It occurs ... stem from a disturbance in the immune system that allows bacteria ...
... A balance is needed between geographic convenience and the ... patients in remote areas, according to an article// in ... (MJA). ,There is a developing trend towards ... to maintain service quality and care standards. ...
Cached Medicine News:Health News:Exercise Important in Reducing Size of Abdominal Fat Cells 2Health News:Bolster Rural Surgical Services 2
HemoNIR™ is a portable device that measures the ability of apersons blood to carry oxygen by monitoring functional vs. non functional hemoglobin....
... real-time PCR analysis of gene expression ... LightCycler 480 System combines amazing speed ... the needs of a broad range ... including array validation, gene-knockdown studies, and ...
... Vivid 3 - Vivid family system ... level of cardiovascular performance, and offer an ... vascular, pediatrics and the OR. , ,From ... to DICOM connectivity, the new Vivid 3 ...
... Wireless, internet-based ... provides compliance and ... complete system. The ... System incorporates communication ...
Medicine Products: